Brent R. Bellows, Ph.D. is a partner with Knowles Intellectual Property Strategies (KIPS) in Atlanta, Georgia. Dr. Bellows is also the current Chair of the IP Section of the Georgia State Bar, with a membership of over twelve hundred IP lawyers. In this capacity, Dr. Bellows leads the organization of educational programs, and is the official representative for the State Bar of Georgia for communications with IP Bars and organizations throughout the country. Dr. Bellows has been active in the State Bar of Georgia for the last five years. Dr. Bellows is also a lecturer on IP issues domestically and internationally.
Dr. Bellows has been named a “Rising Star” by Super Lawyers and one of Georgia’s “Legal Elite” by Georgia Trend Magazine in the area of Intellectual Property Law. Dr. Bellows has also been named to Intellectual Asset Management Magazine’s “Intellectual Property Strategy 300” in 2015 and 2016 and is highlighted in Managing IP Magazine’s 2016 IP Stars.
Dr. Bellows focuses on pharmaceutical and biotechnology patent strategy, which includes prosecution, portfolio creation and management, litigation, product clearance, and freedom to operate including competitor analyses. Dr. Bellows represents large and small biopharmaceutical companies, from entry-level and emerging start-ups to global corporations.
Dr. Bellows received a Ph.D. form the University of Alabama at Birmingham in human genetics, where his thesis focused on the identification of tumor antigens and his research covered several disciplines, including molecular biology, molecular genetics, biochemistry, immunology, and virology.
Following graduate school, Dr. Bellows attended the University of Virginia Law School. Thereafter he joined King & Spalding’s IP group in Atlanta. After practicing for several years, Dr. Bellows serves as a law clerk to Judge Charles A. Pannell, Jr. in the Federal District Court for the Northern District of Georgia, where he assisted with all intellectual property cases on Judge Pannell’s docket. In 2010, he joined KIPS as a partner.
Klaus Koenigshausen is the Chief Executive Officer and Founder of MediQuire, a healthcare data analytics platform that helps ambulatory care clinics and payers transition to new payment models. Klaus brings to MediQuire extensive experience in the healthcare industry as an advisor and healthcare-focused investor at Bain Capital. He holds an MBA from Harvard Business School and a biochemistry degree from Cambridge University.
Jorge Ramirez is a Vice President at H.I.G. BioHealth Partners and focuses on development stage and growth investments in the healthcare sector.
Previously, Jorge was with ProQuest Investments, a healthcare focused private equity firm. During his eight years with ProQuest, the firm raised and fully invested two funds totaling $625 million. He represented ProQuest as an observer or board member in several successful companies including: Eagle Pharmaceuticals (NASDAQ: EGRX); Mevion Medical Systems; Revision Optics; Orthocon (acquired by AbyRx); and MethylGene (now, Mirati Pharmaceutics: NASDAQ: MRTX).
Jorge has also held operating roles in healthcare companies. He was the General Manager of Neurology Products at Cyberkinetics Neurotechnology Systems. He led the regulatory and clinical development teams for an epilepsy monitoring device and had P&L responsibility for Cyberkinetics’ research products. Previously, Jorge was a management consultant at Monitor Company focusing on commercialization strategies and M&A engagements in the healthcare and manufacturing industries.
Jorge earned degrees in Neuroscience and Spanish literature from Amherst College, where he graduated magna cum laude. He earned an M.B.A. from Harvard Business School, where he was a Pfizer Scholar and Social Enterprise Fellow.
Tiffany has spent over a decade bringing innovative medical technology from benchtop to bedside. She leads the Global Center for Medical Innovation, a non-profit organization that represents the Southeast’s first medical device innovation center. At GCMI, Tiffany works with universities, clinicians, industry, investors, and startups focused on innovation, patient care, and economic growth.
Tiffany joined GCMI from Scientific Intake, where she was VP of Business Development & Strategy.Prior to that, she launched ACell as VP of Corporate Strategy & Finance, leading a broad range of initiatives, including market analysis, regulatory, reimbursement, and the scientific advisory board. A former consultant & investment banker, she brings considerable experience in strategic planning, business development, operations, and financial analysis.
Tiffany serves as Past-President of the Board of the Southeast Medical Device Association (SEMDA) and is the Chair of the T3 Labs Advisory Board. She is a Member of the National Advisory Council on Innovation and Entrepreneurship (NACIE) at the U.S. Department of Commerce. She led the Sponsorship Committee of the 2013 SEMDA Conference and has served as the Co-Chair of the Medical Device Subcommittee of the Metro Atlanta Chamber Bioscience Leadership Council. In 2015 she received the prestigious Georgia Bio Community Award.
Tiffany earned her BBA in International Business from Loyola University in New Orleans and an MBA from the Georgetown University McDonough School of Business.
Mark Dempster joined Stifel as a Managing Director in Healthcare Investment Banking in connection with Stifel’s acquisition of Thomas Weisel Partners LLC in July 2010. Mr. Dempster joined Thomas Weisel Partners in 2008 and is based in New York. Within the healthcare space, Mr. Dempster focuses on the biotechnology and specialty pharmaceuticals subsectors.
Mr. Dempster has over 20 years of experience in both investment banking and consulting. Prior to joining Thomas Weisel Partners, Mr. Dempster was a Principal in the Healthcare Investment Banking Group at Banc of America Securities where he focused on the biotechnology and specialty pharmaceuticals subsectors. Mr. Dempster began his investment banking career at JP Morgan Securities in the Mergers & Acquisitions group. Previously Mr. Dempster was as a consultant with Andersen Consulting (now Accenture).
Mark S. Long Director Sid Martin Biotechnology InstituteMark S. Long is the Director of the Sid Martin Biotechnology Institute in Progress Park. Mark was a Senior Lecturer in Entrepreneurship at the Indiana University Kelley School of Business, & President of Long Performance Advisors, LLC, a global consulting company focused on accelerating efforts in business incubation, technology transfer, marketing, small business formation and economic development. Mark received the International Business Innovation Association (InBIA) 2014 President’s Award for Lifetime Achievement in Business Incubation. Mark has an A.S. degree in Medical Technology from Indian River State College, Ft. Pierce, Florida (2007 Alumni Award Winner); B.S. degree in Biology and M.S. degree in Molecular Biology from Florida State University in Tallahassee, Florida.
Dr. Sayour is an Assistant Professor of Pediatrics and Principal Investigator of the RNA Engineering Laboratory at the University of Florida Brain Tumor Immunotherapy Program. He received his B.S. from Fordham University, his M.D. from the University at Buffalo, and his Ph.D. from Duke University. He was a resident in pediatrics at Cohen’s Children’s Medical Center (NY) and completed fellowship training at Duke University Medical Center. Dr. Sayour is an NIH funded investigator with a primary research focus in immuno-oncology. Specifically, he focuses on development tumor RNA loaded nanocarriers to re-direct host immunity against pediatric brain tumors.
Bio Coming Soon
John W. Dombrosky serves as Chief Executive Officer (CEO) of AgTech Accelerator. Built with a consortium of leading venture and industry strategic investors, AgTech Accelerator identifies, forms, develops, and profitably manages the most promising early-stage agricultural technology companies.
Prior to joining AgTech Accelerator™, Mr. Dombrosky spent eight years at Syngenta, where his responsibilities spanned biotech trait licensing, litigation valuation, mergers and acquisitions, strategic planning, P&L management roles. In addition to his experience in the agriculture sector, Mr. Dombrosky served at Thomson Reuters in finance, M&A, and acquisition integration roles, and as an Operational and Corporate Finance analyst at Northwest Airlines.
Mr. Dombrosky has developed a keen eye for transformative technology and an operational sense to help large organizations fully capture it., and has applied this philosophy in operating environments from early stage company formation, to high growth digital platforms, to mature business turn-arounds.
Mr. Dombrosky earned a Bachelor of Arts in Financial Management from the University of St. Thomas and an MBA from the University of Notre Dame.
Tina Williams McKeon is a registered patent attorney who focuses her practice on patent prosecution, IP strategy and IP portfolio management for leading universities, research institutions, and corporations in the life sciences and biotechnology fields. Her biotechnology experience includes neuroscience, immunology, therapeutic antibodies, oncolytic virus therapy, stem cell technology and recombinant technologies in a variety of areas including food and food supplements. Dr. McKeon has worked extensively with medical technology and pharmaceuticals, including cardiac technology, imaging and diagnostics as well as small molecule pharmaceuticals and biologics.
Dr. McKeon contributes her talent and time to a number of bioscience and medical device organizations. Since 2005, she has taught in the TI:GER® Program, a collaboration between Emory University School of Law and Georgia Institute of Technology, that focuses on technology commercialization in a multidisciplinary context. She is also a frequent lecturer regarding the role of intellectual property in entrepreneurship and has served as adjunct faculty at Emory Law School. Dr. McKeon is the author of more than 14 scientific publications.
Randy joined Garheng in starting HealthQuest in 2013. After a successful career as a MedTech entrepreneur, Randy switched careers because he also saw the opportunities overlooked by investors and felt he could help innovative young businesses by applying the lessons he learned by leading those kinds of companies. He is currently on the board of HealthQuest portfolio companies Vestagen, Virmeica and Avizia and is a Board observer on Magnolia Medical, Trice Medical and FAST.
Randy’s industry successes include starting NovaMin Technology, Inc. leading it through financing, growth and eventual acquisition by GlaxoSmithKline (at a 10x return on capital); a turn-around of USBiomaterials Corp’s bone-grafting business from perennial money-loser to a profitable spin-out (now NovaBone Products); and a member of the early management team at LensCrafters as it emerged from start-up to market leader. These businesses each solved real problems for patients and users and those are the kind of opportunities Randy seeks as he thinks about opportunities at HealthQuest.
Randy is committed to supporting entrepreneurs both in HealthQuest’s portfolio and beyond, including as past chair of the Gainesville Area Innovation Network, board member of the Cade Museum of Invention and Creativity, advisory board member for the Florida Institute for the Commercialization of Public Research.
Randy graduated from Georgia Tech with a BS in Management Science. He spent the first half of his career in consumer products marketing, starting in brand management at Procter & Gamble in Cincinnati. Randy lives in Gainesville, Florida with his wife and three sons with whom he enjoys wilderness backpacking.
Dean Erhardt offers over 25 years of strategic marketing and management experience across both the consumer product and pharmaceutical arenas. His areas of expertise include analysis and development of pharmaceutical support programs, pharmaceutical and consumer product distribution, and specialty pharmaceutical product management. Mr. Erhardt’s experience has spanned several Fortune 500 organizations including Express Scripts, Cardinal Health and U.S. Healthcare.
Since launching D2 in 2008, D2 has worked with over 300 companies launching multiple pharmaceutical, biotech, medical device and e-Health products. In addition, D2 has worked with numerous distribution entities in the areas of specialty distribution, specialty pharmacy, URAC accreditation, ACHC accreditation, operational policies and procedures and other related activities.
Currently, Mr. Erhardt supports companies in the launching and reimbursement of pharmaceutical, biotech, medical device and e-health products across the Specialty Pharmacy, Specialty Distribution, Retail, Long-Term Care, and Hospital Markets including limited and exclusive distribution models requiring REMS. Additionally, Dean leads the D2 efforts in working with companies addressing Managed Care and Government payer market access issues.
In addition to his duties with D2, Mr. Erhardt sits on the Board of Trustees for STAGES St. Louis and the Board of Directors for VirMedica Inc.
Mr. Erhardt has a BA in Marketing from the University of Oklahoma and an MBA from the Keller Graduate School of Management.
Dr. Nicholson is CEO of Nimbus Therapeutics, based in Cambridge MA. He joined Nimbus in 2014 after 25yrs at Merck where he held various strategic, leadership and operational roles in diverse therapeutic areas, including respiratory, inflammation, immunology, bone, endocrine, urology, infectious diseases and neurosciences. He began his career in 1988 at the Merck-Frosst Centre for Therapeutic Research in Montreal and advanced through various positions of increasing responsibility including Vice President & Site Head of the Merck Neurosciences Research site in San Diego, Calif., and most recently as Vice President and Worldwide Discovery Head for the Respiratory & Immunology Franchise, based in Kenilworth, N.J. Dr. Nicholson has co-authored more than 150 publications in peer-reviewed scientific and medical journals and is internationally-recognized for his contributions to the field of apoptotic cell death. He received his Ph.D. and an Honors B.Sc. degree in biochemistry from the University of Western Ontario, and trained as a Medical Research Council post-doctoral fellow at the University of Munich in Germany. He is the recipient of multiple academic and professional honors.
Carter leads the economic development team and is responsible for the Institute’s relationships with local, state, and federal government officials, site selectors, and the associate companies. A native Huntsvillian, Carter brings to the role a wealth of experience, having served as Chief of Staff for U.S. Representative Bud Cramer and as CEO of biotech start-up iCubate. He is also an executive committee member and past chairman of BioAlabama, a statewide organization that represents Alabama’s bio-related industries, research institutes, and academia all working together to foster, develop and support the life sciences in Alabama. Carter also serves on the boards of the Business Council of Alabama and the startup incubator BizTech.